Sanofi SA

SNW

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    74,846

Stocks News & Analysis

stocks

Nvidia earnings: Business as usual as forecasts suggest that all is well

Are the shares cheap?
stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,932.4064.90-0.72%
CAC 408,162.4154.37-0.66%
DAX 4025,811.95233.42-0.90%
Dow JONES (US)50,205.93553.49-1.09%
FTSE 10010,561.08128.79-1.20%
HKSE23,294.75213.42-0.91%
NASDAQ24,394.5466.150.27%
Nikkei 22559,024.28163.850.28%
NZX 50 Index14,264.2942.67-0.30%
S&P 5007,322.1418.39-0.25%
S&P/ASX 2008,821.8061.40-0.69%
SSE Composite Index3,587.833.250.09%

Market Movers